文献速递泌尿男性生殖肿瘤支持与姑息治疗

恩扎卢胺或安慰剂治疗非转移性去势抵抗性前列腺癌患者后的患者报告结局(PROSPER):一项多中心、随机、双盲、3期试验

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-02-12

PROSPER试验中,恩扎卢胺显著改善非转移性去势抵抗性前列腺癌患者的无转移生存。本文报告患者报告结局:恩扎卢胺组至临床意义疼痛进展时间、泌尿症状和肠道症状恶化时间、FACT-P总分及情绪健康等恶化时间均长于安慰剂组,但激素治疗相关症状恶化时间更短,多数差异未达临床意义。

要点

  • 恩扎卢胺组至BPI-SF疼痛严重程度临床意义进展中位时间36.83个月,安慰剂组未达到(HR 0.75,p=0.028)。
  • 恩扎卢胺组至EORTC QLQ-PR25泌尿症状恶化中位时间36.86个月 vs 安慰剂组25.86个月(HR 0.58,p<0.0001)。
  • 恩扎卢胺组至激素治疗相关症状恶化中位时间33.15个月 vs 安慰剂组36.83个月(HR 1.29,p=0.035)。

核心结论

  • 接受恩扎卢胺的非转移性去势抵抗性前列腺癌患者无转移生存期长于安慰剂组,同时维持低疼痛水平、低前列腺癌症状负担和高健康相关生活质量。
  • 与安慰剂相比,恩扎卢胺通过延迟疼痛进展、症状恶化和功能状态下降显示出临床获益。
  • 这些发现提示恩扎卢胺是一种应与高危、非转移性去势抵抗性前列腺癌患者讨论的治疗选择。

研究设计与样本

  • 随机、双盲、安慰剂对照、3期PROSPER试验,在全球254个研究中心进行。
  • 纳入18岁及以上、非转移性去势抵抗性前列腺癌且前列腺特异性抗原倍增时间不超过10个月的患者。
  • 通过交互式语音网络识别系统按2:1随机分配接受口服恩扎卢胺(每日160 mg)或安慰剂。
  • 随机化按前列腺特异性抗原倍增时间和基线骨靶向药物使用分层。
  • 主要终点为无转移生存,已在别处报告;本次报告次要疗效终点为疼痛进展和健康相关生活质量。

主要发现

  • 2013年11月26日至2017年6月28日共入组1401例患者,随机分配至恩扎卢胺组(n=933)或安慰剂组(n=468)。
  • 恩扎卢胺组中位随访18.5个月(IQR 10.7-29.2),安慰剂组15.1个月(IQR 7.4-25.9)。
  • 基线患者报告结局评分两组相似。
  • 从基线至第97周最小二乘均值变化:FACT-P社会/家庭福祉恩扎卢胺组0.30(95%CI -0.25至0.85)vs 安慰剂组-0.64(95%CI -1.51至0.24),差异0.94(95%CI 0.02至1.85),p=0.045,利于恩扎卢胺。
  • 从基线至第97周最小二乘均值变化:EORTC QLQ-PR25激素治疗相关症状恩扎卢胺组1.55(95%CI 0.26至2.83)vs 安慰剂组-1.83(95%CI -3.86至0.20),差异3.38(95%CI 1.24至5.51),p=0.0020,不利于恩扎卢胺;上述两项变化均未达临床意义。

关键数值与推荐

  • 疼痛进展通过简明疼痛评估量表简表(BPI-SF)评估,采用预设问卷阈值确定临床意义变化。
  • 健康相关生活质量通过欧洲癌症研究与治疗组织生活质量问卷(EORTC QLQ-PR25)、EuroQoL五维五水平健康问卷视觉模拟量表(EQ-5D-FL, EQ-VAS)和癌症治疗功能评估-前列腺(FACT-P)问卷评估。
  • 患者在基线、第17周及此后每16周完成问卷直至治疗终止。

临床怎么用

  • 作者认为,恩扎卢胺是一种应与高危、非转移性去势抵抗性前列腺癌患者讨论的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the PROSPER trial, enzalutamide significantly improved metastasis-free survival in patients with non-metastatic, castration-resistant prostate cancer. Here, we report the results of patient-reported outcomes of this study. METHODS: In the randomised, double-blind, placebo-controlled, phase 3 PROSPER trial, done at 254 study sites worldwide, patients aged 18 years or older with non-metastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 months were randomly assigned (2:1) via an interactive voice web recognition system to receive oral enzalutamide (160 mg per day) or placebo. Randomisation was stratified by prostate-specific antigen doubling time and baseline use of a bone-targeting agent. The primary endpoint was metastasis-free survival, reported elsewhere. Secondary efficacy endpoints, reported here, were pain progression (assessed by the Brief Pain Inventory Short Form [BPI-SF] questionnaire) and health-related quality of life (assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-PR25], the EuroQoL 5-Dimensions 5-Levels health questionnaire visual analogue scale [EQ-5D-FL, EQ-VAS], and the Functional Assessment of Cancer Therapy-Prostate [FACT-P] questionnaires). Patients completed questionnaires at baseline, week 17, and every 16 weeks thereafter until treatment discontinuation. We used predefined questionnaire thresholds to identify clinically meaningful changes. Enrolment for PROSPER is complete and follow-up continues. This trial is registered with ClinicalTrials.gov, number NCT02003924. FINDINGS: Between Nov 26, 2013, and June 28, 2017, 1401 patients were enrolled and randomly assigned to receive enzalutamide (n=933) or placebo (n=468). Median follow-up was 18·5 months (IQR 10·7-29·2) in the enzalutamide group and 15·1 months (7·4-25·9) in the placebo group. Patient-reported outcome scores at baseline were similar between groups. Changes in least squares mean from baseline to week 97 favoured enzalutamide versus placebo for FACT-P social and family wellbeing (0·30 [95% CI -0·25 to 0·85] vs -0·64 [-1·51 to 0·24]; difference 0·94 [95% CI 0·02 to 1·85]; p=0·045) and disfavoured enzalutamide versus placebo for EORTC QLQ-PR25 hormonal treatment-related symptoms (1·55 [0·26 to 2·83) vs -1·83 [-3·86 to 0·20]; difference 3·38 [1·24 to 5·51]; p=0·0020); neither of these changes were clinically meaningful. No significant differences were observed between treatments for changes from baseline to week 97 in any other patient-reported outcome score. Time to clinically meaningful pain progression as assessed by BPI-SF pain severity was longer with enzalutamide than with placebo (median 36·83 months, [95% CI 34·69 to not reached [NR] vs NR; hazard ratio [HR] 0·75 [95% CI 0·57 to 0·97]; p=0·028); there was no significant difference for BPI-SF item 3 or pain interference. Time to clinically meaningful symptom worsening was longer with enzalutamide than with placebo for EORTC QLQ-PR25 urinary symptoms (median 36·86 months [95% CI 33·35 to NR] vs 25·86 [18·53 to 29·47]; HR 0·58 [95% CI 0·46 to 0·72]; p<0·0001) and bowel symptoms (33·15 [29·50 to NR] vs 25·89 [18·43 to 29·67]; 0·72 [0·59 to 0·89]; p=0·0018), and clinically meaningful health-related quality of life as assessed by FACT-P total score (22·11 [18·63 to 25·86] vs 18·43 [14·85-19·35]; 0·83 [0·69 to 0·99]; p=0·037), emotional wellbeing (36·73 [33·12 to 38·21] vs 29·47 [22·18 to 33·15]; 0·69 [0·55 to 0·86]; p=0·0008), and prostate cancer subscale (18·43 [14·85 to 18·66] vs 14·69 [11·07 to 16·20]; 0·79 [0·67 to 0·93]; p=0·0042), although there was no significant difference for other FACT-P scores. Time to clinically meaningful deterioration in EORTC QLQ-PR25 hormonal treatment-related symptoms was shorter with enzalutamide than with placebo (median 33·15 months [95% CI 29·60 to NR] vs 36·83 [29·47 to NR]; HR 1·29 [95% CI 1·02 to 1·63]; p=0·035). Time to deterioration of EQ-VAS was significantly longer for enzalutamide than for placebo (median 22·11 months [95% CI 18·46 to 25·66] vs 14·75 [11·07 to 18·17]; HR 0·75 [95% CI 0·63 to 0·90]; p=0·0013). INTERPRETATION: Patients with non-metastatic, castration-resistant prostate cancer receiving enzalutamide had longer metastasis-free survival than did those who received placebo, while maintaining low pain levels and prostate cancer symptom burden and high health-related quality of life. Enzalutamide showed a clinical benefit by delaying pain progression, symptom worsening, and decrease in functional status, compared with placebo. These findings suggest that enzalutamide is a treatment option that should be discussed with patients presenting with high-risk, non- metastatic, castration-resistant prostate cancer. FUNDING: Astellas Pharma Inc, Medivation LLC (a Pfizer Company).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tombal B, Saad F, Penson D, et al. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2019. PMID: 30770294. doi:10.1016/S1470-2045(18)30898-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。